Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse

Haematologica. 2005 Jun;90(6):861-2.

Abstract

We report two cases of multiple myeloma relapse and progression following a combination of autologous stem cell transplantation and non-myeloablative allogeneic stem cell transplantation. After failure of donor lymphocyte infusions and thalidomide salvage therapy, the patients were treated successfully with bortezomib and eventually underwent a second non-myeloablative allogeneic stem cell transplantation.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Combined Modality Therapy
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Male
  • Middle Aged
  • Pyrazines / therapeutic use*
  • Recurrence
  • Salvage Therapy
  • Stem Cell Transplantation / methods*
  • Thalidomide / therapeutic use
  • Transplantation Conditioning
  • Transplantation, Autologous
  • Transplantation, Homologous / methods*

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib